Infliximab: a new therapeutic agent in acute pancreatitis?
Chimeric TNF antibody, infliximab, should be evaluated for treatment of acute pancreatitis.
These results implicate the bevacizumab-increased efficacy of adriamycin via an inhibition of survivin expression in malignant cells as well as tumor vasculature cells, which provides other insights into the mechanism of enhanced efficacy by combination of VEGF blocker and chemotherapeutic agents.